239 related articles for article (PubMed ID: 32132978)
1. Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.
Tong A; Li M; Cui Y; Ma X; Wang H; Li Y
Front Endocrinol (Lausanne); 2020; 11():61. PubMed ID: 32132978
[No Abstract] [Full Text] [Related]
2. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
3. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
Perez K; Jacene H; Hornick JL; Ma C; Vaz N; Brais LK; Alexander H; Baddoo W; Astone K; Esplin ED; Garcia J; Halperin DM; Kulke MH; Chan JA
Endocr Relat Cancer; 2022 Sep; 29(9):533-544. PubMed ID: 35731023
[TBL] [Abstract][Full Text] [Related]
4. An aggressive cabergoline-resistant, temozolomide-responsive macroprolactinoma due to a germline
Alzahrani AS; Bin Nafisah A; Alswailem M; Moria Y; Poprawski D; Al-Hindi H; Pacak K
Front Endocrinol (Lausanne); 2023; 14():1273093. PubMed ID: 38152133
[TBL] [Abstract][Full Text] [Related]
5. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Schwartz S; Szeto C; Tian Y; Cecchi F; Corallo S; Calegari MA; Di Bartolomeo M; Morano F; Raimondi A; Fucà G; Martinetti A; De Pascalis I; Martini M; Belfiore A; Milione M; Orlandi A; Barault L; Barone C; de Braud F; Di Nicolantonio F; Benz S; Hembrough T; Pietrantonio F
Eur J Cancer; 2019 Jan; 107():164-174. PubMed ID: 30579113
[TBL] [Abstract][Full Text] [Related]
6. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
7. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Mathur R; Zhang Y; Grimmer MR; Hong C; Zhang M; Bollam S; Petrecca K; Clarke J; Berger MS; Phillips JJ; Oberheim-Bush NA; Molinaro AM; Chang SM; Costello JF
Neuro Oncol; 2020 Nov; 22(11):1580-1590. PubMed ID: 32166314
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma.
Ferrara AM; Lombardi G; Pambuku A; Meringolo D; Bertorelle R; Nardin M; Schiavi F; Iacobone M; Opocher G; Zagonel V; Zovato S
Anticancer Drugs; 2018 Jan; 29(1):102-105. PubMed ID: 29099418
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
[TBL] [Abstract][Full Text] [Related]
10. The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Urquhart C; Fleming B; Harper I; Aloj L; Armstrong R; Hook L; Long AM; Jackson C; Gallagher FA; McLean MA; Tarpey P; Kosmoliaptsis V; Nicholson J; Hendriks AEJ; Casey RT
Front Endocrinol (Lausanne); 2022; 13():1066208. PubMed ID: 36440187
[TBL] [Abstract][Full Text] [Related]
11. Differences in Clinical Manifestations and Tumor Features Between Metastatic Pheochromocytoma/Paraganglioma Patients With and Without Germline SDHB Mutation.
Cui Y; Ma X; Wang F; Wang H; Zhou T; Chen S; Tong A; Li Y
Endocr Pract; 2021 Apr; 27(4):348-353. PubMed ID: 34024343
[TBL] [Abstract][Full Text] [Related]
12. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
13. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
van Thuijl HF; Mazor T; Johnson BE; Fouse SD; Aihara K; Hong C; Malmström A; Hallbeck M; Heimans JJ; Kloezeman JJ; Stenmark-Askmalm M; Lamfers ML; Saito N; Aburatani H; Mukasa A; Berger MS; Söderkvist P; Taylor BS; Molinaro AM; Wesseling P; Reijneveld JC; Chang SM; Ylstra B; Costello JF
Acta Neuropathol; 2015 Apr; 129(4):597-607. PubMed ID: 25724300
[TBL] [Abstract][Full Text] [Related]
14. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
[TBL] [Abstract][Full Text] [Related]
16. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
[TBL] [Abstract][Full Text] [Related]
17. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
[TBL] [Abstract][Full Text] [Related]
19. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
Wick W; Dettmer S; Berberich A; Kessler T; Karapanagiotou-Schenkel I; Wick A; Winkler F; Pfaff E; Brors B; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Eisenmenger A; von Deimling A; Jones DTW; Pfister SM; Sahm F; Platten M
Neuro Oncol; 2019 Jan; 21(1):95-105. PubMed ID: 30277538
[TBL] [Abstract][Full Text] [Related]
20. Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor phenotype and predisposing mutation.
Kiss NB; Muth A; Andreasson A; Juhlin CC; Geli J; Bäckdahl M; Höög A; Wängberg B; Nilsson O; Ahlman H; Larsson C
Endocr Relat Cancer; 2013 Feb; 20(1):65-78. PubMed ID: 23154831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
